Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0W9YW
|
|||
| Drug Name |
Spesolimab
|
|||
| Synonyms |
BI-655130
Click to Show/Hide
|
|||
| Indication | Psoriasis vulgaris [ICD-11: EA90; ICD-10: L40] | Approved | [1] | |
| Palmoplantar pustulosis [ICD-11: EA90.42; ICD-10: L40.3] | Phase 2 | [2] | ||
| Plaque psoriasis [ICD-11: EA90.0; ICD-10: L40.1] | Phase 2 | [2] | ||
| Company |
Boehringer Ingelheim
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | IL-1 receptor-like 2 (IL1RL2) | Target Info | Antagonist | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761244. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.